UCB SA (0NZT.IL) Stock
UCB SA

Company profile
UCB SA reported revenue of 7.74 billion EUR for fiscal year 2025, and net income of 1.56 billion EUR. That is a net profit margin of 20.1% for fiscal year 2025. Our analysis of its filings shows revenue growing from 5.25 billion EUR in fiscal year 2023 to 7.74 billion EUR in fiscal year 2025, 21.4% a year on average. UCB SA reports about 8,600 full-time employees.
What stands out
- Revenue rose 25.8% in fiscal year 2025, from 6.15 billion EUR in fiscal year 2024, after a rise of 17.1% the year before.
- It spent 1.82 billion EUR on research and development in fiscal year 2025, 23.5% of its revenue.
Figures from company filings; latest fiscal year ended December 31, 2025.
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Leadership
- Jean-Christophe Tellier — CEO & Exec. Director, 63
- Sandrine Dufour CFA — Exec. VP & CFO & Chief Corp. Devel., 56
- Caroline Vancoillie — Chief Accounting Officer, Head of Group Fin. & CFO of Patient Value Functions
- Dhavalkumar D. Patel M.D., Ph.D. — Exec. VP & Chief Scientific Officer, 61
- Jean-Luc Fleurial — Exec. VP & Chief HR Officer, 57
How much revenue does UCB SA make?
UCB SA reported 7.74 billion EUR in revenue for fiscal year 2025, up 25.8% from 6.15 billion EUR in fiscal year 2024.
What companies are similar to UCB SA?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (0QFP.IL), Grifols, S.a. (0RDV.IL), Hikma Pharmaceuticals PLC (HIK.L), International Biotechnology Ord (IBT.L).
How has UCB SA's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 5.78 billion EUR; FY2022, 5.52 billion EUR; FY2023, 5.25 billion EUR; FY2024, 6.15 billion EUR; FY2025, 7.74 billion EUR.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “UCB SA (0NZT.IL)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/0NZT.IL